Pharma Focus Asia

Chugai Pharmaceutical Invests US$0.35 billion (50 billion Yen) to Open New Manufacturing Facilities

Introduction: 
Chugai Pharmaceutical has unveiled its plans to construct a new facility dedicated to the manufacturing of bioactive pharmaceutical ingredients (APIs) as well as an injection building.  The two facilities will be loacted in Japan. 

Features:
The newly constructed bio-API manufacturing building (UT3) will be specifically designed to facilitate the transition from clinical development to initial commercial production of bio-APIs (biologically active pharmaceutical ingredients).

Its primary purpose is to serve as a dedicated facility for middle to later-stage manufacturing of investigational drugs.

The new manufacturing facilities, UT3 and UTA, will play a significant role in promoting environmental burden reduction. These facilities will incorporate various environmentally friendly features, such as chlorofluorocarbon-free design and energy-saving technologies. 

The construction of the new bio-API manufacturing building (UK4) for early-stage clinical development and the existing facilities will create a comprehensive in-house supply foundation. This integrated approach can enhance operational efficiency, shorten lead times, and ensure a reliable and consistent supply of products throughout the development process.

In addition, digital infrastructure will be deployed in both buildings to support the new operations of the production function.

Specifications:

Name    Chugai Pharmaceutical
Type      New Construction
Budget  US$0.35 billion (50 Billion Yen)

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference